Iron-deficiency Clinical Trial
— Fe_GOS_2Official title:
The Effect of Prebiotics on Iron Absorption in Women With Low Iron Stores: Determination of a Dose-dependent Effect of Galacto-oligosaccharides on Iron Absorption, With and Without Addition of Ascorbic Acid
NCT number | NCT03762148 |
Other study ID # | Fe_GOS_2 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | April 1, 2019 |
Est. completion date | June 11, 2019 |
Verified date | July 2019 |
Source | Swiss Federal Institute of Technology |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Iron deficiency is still the most common and widespread nutritional disorder in the world
according to WHO.
In a recent iron absorption study in adult women with low iron stores in our lab (publication
under review), we found that 15 g of GOS given with an iron supplement in the form of iron
fumarate acutely increased iron absorption when given with water and a bread based meal. The
dose of 15 g of GOS was tolerated well by the participants. As a follow up to the study
mentioned above, we want to investigate: 1) if acute iron absorption is affected by lower
doses of GOS; 2) whether this acute effect occurs for other commonly used iron compounds as
well, such as iron sulphate and iron phosphate; and 3) if there are potential interactions on
absorption with other enhancers of iron absorption, such as vitamin c.
Status | Completed |
Enrollment | 46 |
Est. completion date | June 11, 2019 |
Est. primary completion date | June 11, 2019 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: - Female, 18 to 45 years old - SF levels <30 µg/L - Normal body Mass Index (18.5-24.9 kg/m2) - Body weight <70 kg - Signed informed consent Exclusion Criteria: - Severe anaemia (Hb < 80 g/L) - Elevated CRP >10.0 mg/L - Any metabolic, gastrointestinal kidney or chronic disease such as diabetes, renal failure, hepatic dysfunction, hepatitis, hypertension, cancer or cardiovascular diseases (according to the participants own statement) - Continuous/long-term use of medication during the whole studies (except for contraceptives) - Consumption of mineral and vitamin supplements within 2 weeks prior to 1st supplement administration, including pre- and-or probiotics supplements (excluding foods and beverages with life cultures such as yoghurt, raw milk cheese and kombucha) - Blood transfusion, blood donation or significant blood loss (accident, surgery) over the past 4 months - Difficulties with blood sampling - Use of antibiotics over the past month - Known hypersensitivity to iron supplements in the given amount, GOS, or lactose - Women who are pregnant or breast feeding - Women who intend become pregnant during the course of the study - Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, inject-able, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases - Known or suspected non-compliance, drug or alcohol (more than 2 drinks/day) abuse - - Smokers (> 1 cigarette per week) - Inability to follow the procedures of the study, e.g. due to language problems, self-- reported psychological disorders, etc. of the participant - Enrollment of the investigator, his/her family members, employees and other dependent persons |
Country | Name | City | State |
---|---|---|---|
Switzerland | Human Nutrition Laboratory, ETH Zurich | Zurich |
Lead Sponsor | Collaborator |
---|---|
Isabelle Herter-Aeberli | Antistress AG, Gesellschaft für Gesundheitsschutz - Burgerstein Vitamine |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | fractional iron absorption | Fractional iron absorption will be calculated based on the shift of the iron isotope ratios in the collected blood samples after the administration of several isotopically labelled iron supplements.Fractional iron absorption will be measured as erythrocyte incorporation of the naturally occurring iron forms with different masses used to label the iron supplements. | 2 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04949165 -
Bloodsafe Ghana- Iron and Nutritional Counseling Strategy Pilot Study
|
N/A | |
Terminated |
NCT03218384 -
Ferric Carboxymaltose to Improve Skeletal Muscle Metabolism in Heart Failure Patients With Functional Iron Deficiency
|
Phase 2 | |
Active, not recruiting |
NCT03516734 -
Iron-fortified Lentils to Improve Iron (Fe) Status in Bangladesh
|
N/A | |
Completed |
NCT03572010 -
Stable Iron Isotope Method in HIV+ and HIV- Children
|
N/A | |
Active, not recruiting |
NCT03703726 -
Iron Absorption From Fortified Extruded Rice Using Different Extruding Temperatures.
|
N/A | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Not yet recruiting |
NCT05395468 -
Diagnosis of Iron Deficiency by Artificial Intelligence Analysis of Eye Photography.
|
||
Withdrawn |
NCT03800446 -
Validation of a Point-of-care Device Measuring Ferritin With Capillary Blood
|
N/A | |
Not yet recruiting |
NCT03353662 -
Sub Regional Micronutrient Survey in Ethiopia
|
||
Completed |
NCT03819530 -
Child of Urban Poverty Iron Project (CUPIP) - A Pilot Study
|
N/A | |
Recruiting |
NCT04144790 -
Impact of Iron Supplementation Treatment on Brain Iron Concentrations
|
||
Completed |
NCT03957057 -
Intravenous Iron Carboxymaltose, Isomaltoside and Oral Iron Sulphate for Postpartum Anemia
|
Phase 3 | |
Completed |
NCT03642223 -
Central and Peripheral Adiposity and Iron Absorption
|
N/A | |
Not yet recruiting |
NCT05407987 -
Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery)
|
Phase 3 | |
Withdrawn |
NCT03873584 -
Improvement of Fatigue Symptoms in the Iron Deficiency Anemia With Iron Succinylate Therapy
|
||
Enrolling by invitation |
NCT03897673 -
Optimizing Benefits While Reducing Risks of Iron in Malaria-endemic Areas
|
N/A | |
Completed |
NCT04359368 -
Characteristics of Patients With Hypersensitivity Reactions to Intravenous Iron Infusions
|
||
Active, not recruiting |
NCT04778072 -
A Clinical Study on Adherence and Efficacy of Different Doses of Active Iron in Treatment Resistant Subjects
|
N/A | |
Enrolling by invitation |
NCT05750940 -
Oxidative Skeletal Muscle Metabolism in Chronic Heart Failure Patients With and Without Iron Deficiency
|
||
Recruiting |
NCT05126901 -
Evaluate the Safety and Efficacy of Ferric Maltol Oral Suspension vs. Ferrous Sulfate Oral Liquid in Children and Adolescents Aged 2 to 17 Years With Iron-deficiency Anaemia, With a Single Arm Study in Infants Aged 1 Month to Less Than 2 Years
|
Phase 3 |